SCHEMBL30309207

SCHEMBL30309207

NC(=O)c1ccc2c(n1)OCCN2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.47
MAP3K14 Q99558 1/20 0.36
PIM1 P11309 1/20 0.35
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KMT2A Q03164 1/20 0.33
AR P10275 1/20 0.32
GRM2 Q14416 1/20 0.31
MAP4K1 Q92918 1/20 0.31
NNMT P40261 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
LMNA P02545 1/20 0.31
PRKCQ Q04759 1/20 0.31
KDM4E B2RXH2 1/20 0.30
SCN9A Q15858 1/20 0.30
TSHR P16473 1/20 0.30
PDE3B Q13370 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL30309198 0.94 GRM5 (0.43) GRM5MAP3K14PIM1TRPV1
SCHEMBL19859465 0.87 GRM5 (0.50) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL28621555 0.82 GRM5 (0.43) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL29990900 0.75 MAP3K14 (0.37) MAP3K14PIM1ALDH1A1SCN9A
SCHEMBL22048899 0.73 GRM5 (0.51) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL852827 0.73 GRM5 (0.51) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL382392 0.73 GRM5 (0.51) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL14476027 0.72 GRM5 (0.48) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL14476025 0.72 GRM5 (0.48) GRM5ALDH1A1MAPTGAAHSD17B10
SCHEMBL30540616 0.71 PIM1 (0.38) MAP3K14PIM1MAPTKMT2AGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583866-B2 Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists BEONE MEDICINES I GMBH (CH) 2026-03-24 US disclosed
US-20230219975-A1 PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS BEONE MEDICINES I GMBH (CH) 2023-07-13 US disclosed
EP-4161937-A1 PYRIDO[2,3-B] [1,4] OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4] OXAZEPINES AS IAP ANTAGONISTS BeiGene, Ltd. (KY) 2023-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583866-B2 Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists BIRC2, BIRC3, BIRC5 GRM5 3526/4885MAP3K14 1669/4885PIM1 1727/4885
US-20230219975-A1 PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS BIRC2, BIRC3, API5 GRM5 988/4885MAP3K14 1913/4885PIM1 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.